Home › Entities › master_s_thesis › Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial

Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial

2018 master's thesis by Christin Coomarasamy at Auckland University of Technology
Place master_s_thesis Q112227650
Press Enter · cited answer in seconds

Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial

Summary

Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial is a master's thesis[1].

Key Facts

  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial authored Evidence from a cross over randomised trial — author (P50): Christin Coomarasamy[2].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's instance of is recorded as Evidence from a cross over randomised trial — instance of (P31): master's thesis[3].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's publisher is recorded as Evidence from a cross over randomised trial — publisher (P123): Tuwhera Open Access Publisher[4].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's language of work or name is recorded as Evidence from a cross over randomised trial — language of work or name (P407): English[5].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's country of origin is recorded as Evidence from a cross over randomised trial — country of origin (P495): New Zealand[6].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's publication date is recorded as +2018-00-00T00:00:00Z[7].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's Handle ID is recorded as 10292/11557[8].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's title is recorded as Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial[9].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's copyright holder is recorded as Evidence from a cross over randomised trial — copyright holder (P3931): Christin Coomarasamy[10].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's thesis submitted to is recorded as Evidence from a cross over randomised trial — thesis submitted to (P4101): Auckland University of Technology[11].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's on focus list of Wikimedia project is recorded as Evidence from a cross over randomised trial — on focus list of Wikimedia project (P5008): NZThesisProject[12].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's copyright status is recorded as Evidence from a cross over randomised trial — copyright status (P6216): copyrighted[13].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's thesis committee member is recorded as Evidence from a cross over randomised trial — thesis committee member (P9161): Alain C Vandal[14].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's thesis committee member is recorded as Evidence from a cross over randomised trial — thesis committee member (P9161): Braden James Te Ao[15].
  • Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's thesis committee member is recorded as Evidence from a cross over randomised trial — thesis committee member (P9161): Conroy A Wong[16].

Body

Designation and Status

Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial's instance of is recorded as Evidence from a cross over randomised trial — instance of (P31): master's thesis[3].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [3] ↑ . wikidata.org.
  2. [2] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial. Retrieved May 3, 2026, from https://4ort.xyz/entity/cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial
MLA “Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial.
BibTeX @misc{4ortxyz_cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial}}, year = {2026}, url = {https://4ort.xyz/entity/cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial — https://4ort.xyz/entity/cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/cost-effectiveness-and-cost-utility-analysis-of-tiotropium-treatment-for-bronchiectasis-evidence-from-a-cross-over-randomised-trial · Last refreshed: